Predictive Risk Factors for Early Recurrence of Stage pIIIA-N2 Non-Small Cell Lung Cancer

Código QR

Predictive Risk Factors for Early Recurrence of Stage pIIIA-N2 Non-Small Cell Lung Cancer

Qiongjie Yu,&ast; Xuedan Du,&ast; Zhen Fang, Xiaolu Mao, Jinting Wu, Bin Wang, Wenfeng Li Department of Oncology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: W...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yu Q, Du X, Fang Z, Mao X, Wu J, Wang B, Li W
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	non-small cell lung cancer，early recurrence，risk factors inflammatory biomarkers prognosis Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/f02616ec586c424f8e886a3043d0322e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

The Prognostic Role of Blood Inflammatory Biomarkers and EGFR Mutation Status in Stage IIIA/N2 Non-Small Cell Lung Cancer Patients Treated With Trimodality Therapy
por: Hui Yang, et al.
Publicado: (2021)

Identification and Validation of an Immune and Ferroptosis-Combined Index for Non–Small Cell Lung Cancer
por: Yang Teng, et al.
Publicado: (2021)

Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management
por: Maja Šutić, et al.
Publicado: (2021)

Biomarkers for screening of lung cancer and pre-neoplastic lesions in a high risk Chilean population
por: Adonis,Marta I, et al.
Publicado: (2014)

MTA1 Expression Can Stratify the Risk of Patients with Multifocal Non-Small Cell Lung Cancers ≤3 cm
por: Wang W, et al.
Publicado: (2021)

GCC2 as a New Early Diagnostic Biomarker for Non-Small Cell Lung Cancer
por: Hyesun Jeong, et al.
Publicado: (2021)

The role of tumoral stroma in determining the forecast of recurrence and fatal consequence of stage IIA-IIIB colorectal cancer
por: Alina Yakimenko
Publicado: (2021)

Preoperative Systemic Inflammatory Biomarkers Are Independent Predictors of Disease Recurrence in ER+ HER2- Early Breast Cancer
por: Marta Truffi, et al.
Publicado: (2021)

NFAT as a Biomarker and Therapeutic Target in Non–Small Cell Lung Cancer–Related Brain Metastasis
por: Lu Peng, et al.
Publicado: (2021)

Effectiveness of Postoperative or Preoperative Radiotherapy on Prognosis in Patients with Stage II Resectable Non-Small Cell Lung Cancer: A Retrospective Study Based on the SEER Database
por: Deng Chen, et al.
Publicado: (2021)

Biogenesis, functions, and clinical implications of circular RNAs in non-small cell lung cancer
por: Ying Liu, et al.
Publicado: (2022)

Targeting HER2 genomic alterations in non-small cell lung cancer
por: Jie Zeng, et al.
Publicado: (2021)

Prognostic characterization of immune molecular subtypes in non-small cell lung cancer to immunotherapy
por: Chenlu Li, et al.
Publicado: (2021)

Real-world practice patterns for patients with advanced non-small cell lung cancer: multicenter retrospective cohort study in Japan
por: Isobe H, et al.
Publicado: (2017)

Immunotherapy in patients with non-small cell lung cancer with ECOG PS 2
por: Damian Mojsak, et al.
Publicado: (2021)

Association of expression and genotypes of thymidylate synthase in non-small cell lung cancer patients with different clinicopathological characteristics
por: Chen Jin-Yin, et al.
Publicado: (2021)

Hemoglobin A1c level is a prognostic factor for locoregional recurrence in stage III non‐small cell lung cancer patients treated with radiotherapy
por: Moonkyoo Kong, et al.
Publicado: (2021)

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
por: Barrows SM, et al.
Publicado: (2019)

A retrospective study of clinicopathologic and molecular features of inoperable early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy
por: I-Han Lee, et al.
Publicado: (2021)

Stereotactic body radiation therapy (SBRT) in the management of non-small-cell lung cancer: Clinical impact and patient perspectives
por: Donovan EK, et al.
Publicado: (2018)

ANTIBODIES TO BENZO[A]PYRENE IN SERUM OF PATIENTS WITH NON-SMALL CELL LUNG CANCER
por: E. G. Polenok, et al.
Publicado: (2012)

Small cell transformation of non‐small cell lung cancer under immunotherapy: Case series and literature review
por: Takuma Imakita, et al.
Publicado: (2021)

Research on the application of uniportal video-assisted thoracoscopic segmental resection of the lung in elderly patients with non-small cell lung cancer aged over 65 years
por: Hongya Xie, et al.
Publicado: (2021)

Application of multifunctional targeting epirubicin liposomes in the treatment of non-small-cell lung cancer
por: Song X, et al.
Publicado: (2017)

Prospects for the development of adjuvant therapy for non-small cell lung cancer
por: K. K. Laktionov, et al.
Publicado: (2020)

Oligometastatic non-small-cell lung cancer: current treatment strategies
por: Richard PJ, et al.
Publicado: (2016)

Adaptive Radiation Therapy in the Treatment of Lung Cancer: An Overview of the Current State of the Field
por: Huzaifa Piperdi, et al.
Publicado: (2021)

Identification of Prognostic Gene Biomarkers in Non-Small Cell Lung Cancer Progression by Integrated Bioinformatics Analysis
por: Panagiotis Giannos, et al.
Publicado: (2021)

Application of Multifunctional Targeting Epirubicin Liposomes in the Treatment of Non-Small-Cell Lung Cancer [Corrigendum]
por: Song X, et al.
Publicado: (2021)

DNA methylation in lung cancer patients: Opening a 'window of life' under precision medicine
por: Runzhang Liang, et al.
Publicado: (2021)

Clinical utility of ramucirumab in non-small-cell lung cancer
por: Uprety D
Publicado: (2019)

Expression and Significance of CK5/6, P63, P40, CK7, TTF-1, NapsinA, CD56, Syn and CgA in Biopsy Specimen of Squamous Cell Carcinoma, Adenocarcinoma and Small Cell Lung Carcinoma
por: Wang,Jing-yuan, et al.
Publicado: (2020)

Does Clinical and Biochemical Thyroid Dysfunction Impact on Endometrial Cancer Survival Outcomes? A Prospective Database Study
por: Chloe E. Barr, et al.
Publicado: (2021)

Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis
por: Valerio Nardone, et al.
Publicado: (2021)

CYFRA 21-1 in patients with suspected cancer: evaluation of an optimal cutoff to assess the diagnostic efficacy and prognostic value
por: Garcia-Valdecasas Gayo Sonsoles, et al.
Publicado: (2020)

Effect of antibiotic use on the efficacy of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer: A meta-analysis
por: Huo Geng-wei, et al.
Publicado: (2021)

Construction of circRNA-miRNA-mRNA network and identification of novel potential biomarkers for non-small cell lung cancer
por: Jia Yang, et al.
Publicado: (2021)

The Survival Benefit for Optimal Glycemic Control in Advanced Non-Small Cell Lung Cancer Patients With Preexisting Diabetes Mellitus
por: Jie Qian, et al.
Publicado: (2021)

Cancer Stem Cell-Like Circulating Tumor Cells Are Prognostic in Non-Small Cell Lung Cancer
por: Eva Obermayr, et al.
Publicado: (2021)

Four long noncoding RNAs act as biomarkers in lung adenocarcinoma
por: Zhang Zhihui, et al.
Publicado: (2021)